Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	OCT 04	Removal of Pre-IPC 8 data fields streamlines displays in USPATFULL, USPAT2, and USPATOLD.
NEWS 3	OCT 04	Precision of EMBASE searching enhanced with new chemical name field
NEWS 4	OCT 06	Increase your retrieval consistency with new formats or for Taiwanese application numbers in CA/CAplus.
NEWS 5	OCT 21	CA/CAplus kind code changes for Chinese patents increase consistency, save time
NEWS 6	OCT 22	New version of STN Viewer preserves custom highlighting of terms when patent documents are saved in .rtf format
NEWS 7	OCT 28	INPADOCDB/INPAFAMDB: Enhancements to the US national patent classification.
NEWS 8	NOV 03	New format for Korean patent application numbers in CA/CAplus increases consistency, saves time.
NEWS 9	NOV 04	Selected STN databases scheduled for removal on December 31, 2010
NEWS 10	NOV 18	PROUSDDR and SYNTHLINE Scheduled for Removal December 31, 2010 by Request of Prous Science
NEWS 11	NOV 22	Higher System Limits Increase the Power of STN Substance-Based Searching
NEWS 12	NOV 22	Enjoy a free month of INPADOCDB/INPAFAMDB SDIs!
NEWS 13	NOV 24	Search an additional 46,850 records with MEDLINE backfile extension to 1946
NEWS 14	DEC 14	New PNK Field Allows More Precise Crossover among STN Patent Databases
NEWS 15	DEC 18	ReaxysFile available on STN
NEWS 16	DEC 21	CAS Learning Solutions -- a new online training experience
NEWS 17	DEC 22	Value-Added Indexing Improves Access to World Traditional Medicine Patents in CAplus

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 07 JULY 2010.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:35:24 ON 04 JAN 2011

=> file reg
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                         ENTRY   SESSION
FULL ESTIMATED COST   0.23   0.23

FILE 'REGISTRY' ENTERED AT 09:35:33 ON 04 JAN 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 3 JAN 2011 HIGHEST RN 1258268-02-8
DICTIONARY FILE UPDATES: 3 JAN 2011 HIGHEST RN 1258268-02-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2010.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10531594_genus_NEW_20110104.str





chain nodes :
15 16 17 18 19 22 23 24 25 28 31 32 33 34 35
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14
chain bonds :
8-28 15-16 16-17 16-18 18-19 19-22 19-23 22-24 23-25 31-32 32-33 33-34
33-35
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10 9-11 10-14 11-12 12-13
13-14
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 8-28 9-10 9-11 10-14 11-12
12-13 13-14 15-16 31-32 32-33 33-34 33-35
exact bonds :
16-17 16-18 18-19 19-22 19-23 22-24 23-25
isolated ring systems :
containing 1 :

G1:NH2,[*1],[*2]

G2:X,Cl,Br,F,I

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 28:CLASS 31:CLASS 32:CLASS
33:CLASS 34:CLASS 35:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 NH2,[@1],[@2]

G2 X,Cl,Br,F,I

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 09:36:05 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 613 TO ITERATE

100.0% PROCESSED 613 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 10775 TO 13745
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 196.35 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 09:36:14 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 12872 TO ITERATE

100.0% PROCESSED 12872 ITERATIONS 72 ANSWERS
SEARCH TIME: 00.00.01

L3 72 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 196.86 197.09

FILE 'CAPLUS' ENTERED AT 09:36:22 ON 04 JAN 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 4 Jan 2011 VOL 154 ISS 2
FILE LAST UPDATED: 3 Jan 2011 (20110103/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2010

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the fourth quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> s l3
L4          57 L3

=> s l4 and ad<20031020
       4771418 AD<20031020
                  (AD<20031020)
L5           6 L4 AND AD<20031020

=> dup rem l5
PROCESSING COMPLETED FOR L5
L6            6 DUP REM L5 (0 DUPLICATES REMOVED)

=> d l6 1-6 ibib abs hitstr

L6   ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER:        2007:151082  CAPLUS
DOCUMENT NUMBER:         146:198645
TITLE:                   Screening molecules with anti-prion activity in
                         Saccharomyces and uses in treating neurodegenerative
                         diseases
INVENTOR(S):             Blondel, Marc; Cullin, Christophe; Vierfond, Jean
                         Michel; Bertolotti, Anne; Bach, Stephane; Talarek,
                         Nicolas; Mettey, Yvette
PATENT ASSIGNEE(S):      Centre National de la Recherche Scientifique (CNRS ),
                         Fr.; Universite Victor Segalen Bordeaux 2; Universite
                         de Poitiers
SOURCE:                  U.S. Pat. Appl. Publ., 22pp., Cont.-in-part of U.S.
                         Ser. No. 531,594.
                         CODEN: USXXCO
DOCUMENT TYPE:           Patent
LANGUAGE:                English
```

FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070031821	A1	20070208	US 2006-483822	20060711
FR 2846008	A1	20040423	FR 2002-13022	20021018 <--
FR 2846008	B1	20060602		
FR 2846009	A1	20040423	FR 2003-8289	20030707 <--
FR 2846009	B1	20071012		
WO 2004035813	A2	20040429	WO 2003-FR3101	20031020
WO 2004035813	A3	20040715		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20060172337	A1	20060803	US 2005-531594	20051120

PRIORITY APPLN. INFO.:

FR 2002-13022	A	20021018
FR 2003-8289	A	20030707
WO 2003-FR3101	W	20031020
US 2005-531594	A2	20051120

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 146:198645

AB A kit and a method for identifying compds. having anti-prion activity are provided. The kit comprises a yeast of phenotype [PSI+]; an antibiogram; and a prion curing agent in a sub-ED, wherein the yeast has the ade1-14 allele of the ADE1 gene and an inactivated ERG6 gene. Compds. and pharmaceutical compns. having anti-prion activity are also provided, which are useful for treating various neurodegenerative diseases, including polyglutamines expansion associated diseases; Huntington's disease; Kennedy disease; amyotrophic lateral sclerosis; cerebellous autosomic ataxies; dentalorubral-pallidoluysian atrophy; and spino-bulbar amyotrophy. Synergy of action between guanidium chloride and phenanthridine, kastellpaolitines or 6-aminophenanthridine was observed

IT 832-68-8, 6-Aminophenanthridine 651055-79-7
651055-83-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(screening mols. with anti-prion activity in Saccharomyces and uses in treating neurodegenerative diseases)

RN 832-68-8 CAPLUS
CN 6-Phenanthridinamine (CA INDEX NAME)



RN 651055-79-7 CAPLUS
CN 6-Phenanthridinamine, 8-chloro- (CA INDEX NAME)



RN 651055-83-3 CAPLUS
CN 6-Phenanthridinamine, 8-(trifluoromethyl)- (CA INDEX NAME)



L6 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2004:20857 CAPLUS
DOCUMENT NUMBER: 140:92609
TITLE: Allergic disease diagnosis and drug screening with NOR-1 (MINOR) receptor
INVENTOR(S): Hashida, Ryoichi; Kagaya, Shinji; Yayoi, Yoshihiro; Sugita, Yuji; Saito, Hirohisa
PATENT ASSIGNEE(S): Genox Research, Inc., Japan; Japan as Represented by the General Director of Agency of the National Center for Child Health and Development
SOURCE: PCT Int. Appl., 155 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004003198	A1	20040108	WO 2003-JP8199	20030627 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003246102	A1	20040119	AU 2003-246102	20030627 <--
US 20040214192	A1	20041028	US 2003-608863	20030627 <--
US 7115373	B2	20061003		

PRIORITY APPLN. INFO.: JP 2002-188490 A 20020627
WO 2003-JP8199 W 20030627
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB Diagnosis of allergic diseases by measuring the expression level of nuclear receptor NOR-1 (neuron derived orphan receptor) or its encoding

gene and use of NOR-1 (MINOR) receptor for screening of ligands usable as anti-allergic agents, are disclosed. Use of NOR-1 (MINOR) receptor for inducing apoptosis is also claimed. Using differential display method, a gene showing significantly increased expression in eosinophils of a patient in the remission state of atopic dermatitis accompanied by a decrease in eosinophils was successfully identified. It was found that this gene coded for NOR-1 (MINOR) receptor and is usable in diagnosis of and screening drug candidates for allergic diseases. A high throughput screening system constructed from modified mammalian two-hybrid screening was used to screen ligands for the NOR-1 (MINOR) receptor. Prostaglandin (PGA) derivs. having cyclopentanone structure were identified as ligands and from the studies with ligand binding domain (LBD) deletion mutant of the receptor, actual effect of those compds. on the receptor was confirmed. Utilizing pharmacophore modeling, simulation of PGA derivative binding site for NOR-1 (MINOR) receptor was carried out and compds. capable of binding to the receptor binding pocket were selected. It was also found that NOR-1 expression was dramatically induced in peripheral blood eosinophils upon apoptosis stimulation with anti-CD30 antibodies having agonist activity toward CD30.

IT 832-68-8, 6-Phenanthridinamine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(allergic disease diagnosis and drug screening with NOR-1 (MINOR) receptor)
RN 832-68-8 CAPLUS
CN 6-Phenanthridinamine (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2000:900623 CAPLUS
DOCUMENT NUMBER: 134:56585
TITLE: Antagonism of immunostimulatory CpG-oligonucleotides by 4-aminoquinolines and other weak bases
INVENTOR(S): MacFarlane, Donald E.; Strekowski, Lucjan; Manzel, Lori; Ismail, Fyaz; Barlin, Gordon B.
PATENT ASSIGNEE(S): University of Iowa Research Foundation, USA
SOURCE: PCT Int. Appl., 138 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000076982	A1	20001221	WO 2000-US16723	20000616 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,

LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2412345	A1	20001221	CA 2000-2412345	20000616 <--
US 6479504	B1	20021112	US 2000-595875	20000616 <--
EP 1377554	A1	20040107	EP 2000-946819	20000616 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL

PRIORITY APPLN. INFO.: US 1999-139544P P 19990616
WO 2000-US16723 W 20000616

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 134:56585

GI



AB The present invention concerns compns. and methods for inhibiting stimulation of the immune system. The compds. and methods comprise compds. that are analogs and derivs. of chloroquine, such as 4-aminoquinolines, and other weak bases. other weak bases. More particularly, a method of inhibiting immunostimulation in a subject comprises administering an effective amount of a composition containing substituted 4-quinolinamines [I; RA = H, lower alkyl; RB = (un)substituted alkyl, alkenyl, or alkynyl secondary or tertiary amine; R2 = (un)substituted Ph, naphthyl, anthracyl, phenanthryl, or styryl; R3 = R5 = R8 = H; R6, R7 = H, halo] and pharmaceutically acceptable salts thereof to said subject, the 4-quinolinamine composition comprising a compound having the structural formula A. They can be used in preventative and therapeutic treatments of autoimmune diseases and phenomena, transplant rejection such as host-vs.-graft disease and sepsis. A detailed structure-activity relationship (SAR) anal. of quinoline antagonists of immunostimulatory CpG-ODNs was undertaken. The synthesis work together with SAR anal. of the synthesized quinolines culminated in the finding of an extremely active agent (II).

IT 313830-96-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of aminoquinolines as antagonists for immunostimulatory CpG-oligonucleotides for presentation and therapeutic treatment of autoimmune diseases and transplant rejection such as host-vs.-graft disease and sepsis)

RN 313830-96-5 CAPLUS

CN 1,3-Propanediamine, N1,N1-dimethyl-N3-6-phenanthridinyl- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 1999:529135 CAPLUS
DOCUMENT NUMBER: 131:157716
TITLE: Preparation of annelated 3,4-dihydroquinolines as nitric oxide synthase inhibitors
INVENTOR(S): Jaroch, Stefan; Rehwinkel, Hartmut; Holscher, Peter; Sulzle, Detlev; Hillmann, Margrit; Burton, Gerardine Anne; McDonald, Fiona Mcdougall
PATENT ASSIGNEE(S): Schering A.-G., Germany
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9941240	A1	19990819	WO 1999-DE382	19990209 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19806348	A1	19990819	DE 1998-19806348	19980212 <--
AU 9929211	A	19990830	AU 1999-29211	19990209 <--
EP 1054869	A1	20001129	EP 1999-910126	19990209 <--
EP 1054869	B1	20040922		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002503652	T	20020205	JP 2000-531435	19990209 <--
AT 277018	T	20041015	AT 1999-910126	19990209 <--
PT 1054869	E	20050228	PT 1999-910126	19990209 <--
ES 2229688	T3	20050416	ES 1999-910126	19990209 <--
US 6391887	B1	20020521	US 2000-622259	20000814 <--

PRIORITY APPLN. INFO.: DE 1998-19806348 A 19980212
WO 1999-DE382 W 19990209
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 131:157716
GI



I

AB Title compds. [I;R1,R2 = H, alkyl, acyl, etc.; R4-R7 = H, halo, alkyl, alkoxy, etc.; Z = (un)substituted (heteroatom-containing)(oxo)alkylene] were prepared Thus, 3-(MeO)C6H4NCO was condensed with 1-morpholinocyclopentene to give 3-(MeO)C6H4NHCOR (R = 2-oxocyclopentenyl) which was cyclized and the product converted in 3 steps to I [R1 = R2 = R4 = R4 = R7 = H, R6 = OMe, Z = (CH2)3]. Data for biol. activity of I were given.

IT 237399-55-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of annelated 3,4-dihydroquinolines as nitric oxide synthase inhibitors)

RN 237399-55-2 CAPLUS

CN 6-Phenanthridinamine, 6a,7,8,9,10,10a-hexahydro- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1995:416192 CAPLUS

DOCUMENT NUMBER: 122:187249

ORIGINAL REFERENCE NO.: 122:34295a,34298a

TITLE: Preparation of 2-phenanthridinylcarbapenems as antibacterial agents

INVENTOR(S): Dininno, Frank P.; Greenlee, Mark L.; Rano, Thomas A.; Lee, Wendy

PATENT ASSIGNEE(S): Merck and Co., Inc., USA

SOURCE: PCT Int. Appl., 115 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9417066	A1	19940804	WO 1994-US85	19940103 <--

W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KR, KZ, LK, LV, MG,

MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, UZ
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,
BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

US 5336674	A	19940809	US 1993-9626	19930127	<--
CA 2154276	A1	19940804	CA 1994-2154276	19940103	<--
AU 9459902	A	19940815	AU 1994-59902	19940103	<--
EP 682666	A1	19951122	EP 1994-906014	19940103	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE					
JP 08505874	T	19960625	JP 1994-517039	19940103	<--

PRIORITY APPLN. INFO.: US 1993-9626 A 19930127
WO 1994-US85 W 19940103
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 122:187249
GI



AB Title compds. [I; M = H, alkali metal, neg. charge, etc.; .; R = H, Me; R1,R2 = H, Me, Et, CH2OH, MeCH(OH), etc.; .; Y = phenanthridinyl group Q; 1 of Ra = H and the others = H, CF3, halo, (un)substituted alkoxy; 1 of X,X1 = N+Rdm and the other = CRc; Rc = H, (un)substituted alkyl(oxy), NH2, etc.; .; Rd = H, NH2, O-, alkyl, etc.; .; m = 0 or 1] were prepared as antibacterial agents (no data). Thus, oxopenamcarboxylate II [M = CH2C6H4(NO2)-4, R3R4 = O, R5 = H] was condensed with Me3SnQ CF3SO3- (Ra = H, X = N+Me, X1 = CH) and the product hydrogenolized to give II (M = neg. charge, R3 = Q, R4R5 = bond, Ra = H, X = N+Me, X1 = CH).

IT 161547-28-0P 161548-17-0P 161549-06-0P
161549-95-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenanthridinylcarbapenems as antibacterial agents)

RN 161547-28-0 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-(6-amino-2-phenanthridinyl)-6-(1-hydroxyethyl)-7-oxo-, [5R-[5α,6α(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 161548-17-0 CAPLUS
CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-(6-amino-9-phenanthridinyl)-6-(1-hydroxyethyl)-7-oxo-, [5S-[5α,6β(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 161549-06-0 CAPLUS
CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-(6-amino-3-phenanthridinyl)-6-(1-hydroxyethyl)-7-oxo-, [5R-[5α,6α(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 161549-95-7 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-(6-amino-8-phenanthridinyl)-6-(1-hydroxyethyl)-7-oxo-, [5R-[5α,6α(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 1939:22099 CAPLUS
DOCUMENT NUMBER: 33:22099
ORIGINAL REFERENCE NO.: 33:3173a-d
TITLE: Picrylamino compounds; diazalines
INVENTOR(S): Morgan, Gilbert T.; Stewart, Jessie
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 496258		19381128	GB 1937-18527	19370703 <--

AB Picrylamino, compds. are prepared by condensing picryl chloride (I) or an alkyl derivative thereof, e. g., methyl- and dimethyl-picryl chlorides, with a compound containing a tertiary cyclic N atom and an adjacent amino group, e. g., 2-aminopyridine (II), 2-aminoquinoline, 1-aminoisoquinoline, 9-aminophenanthridine and their homologs. By cautious heating, preferably in the presence of PhOH, dimethylaniline, etc., ring closure takes place with formation of dinitro-1,3-diazalines, from which 1,3-diazalines may be obtained by reduction and elimination of the amino groups formed. The products are useful as intermediates for the manufacture of dyes and drugs. Among examples, (1) I is heated in C6H6 solution with II to give N-picryl-2-aminopyridine; when PhMe is used as solvent, ring closure takes place with formation of 1,2-pyrido-7,9-dinitro-4,5-benzo-1,3-diazaline, (2) by heating the diazaline of (1) with an aqueous solution of Na polysulfide, 1,2-pyrido-7,9- or -9,7-nitroamino-4,5-benzo-1,3-diazaline is produced; when H is used as reducing agent under an initial pressure of 5 atmospheric and in the presence of Pt oxide, 1,2-pyrido-7,9-diamino-4,5-benzo-1,3-diazaline (III) is produced while at H pressures maintained at 8-10 atmospheric tetrahydro-III results.

IT 832-68-8, Phenanthridine, 6-amino-
(ring closure of derivs. of)

RN 832-68-8 CAPLUS
CN 6-Phenanthridinamine (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

=> d his

(FILE 'HOME' ENTERED AT 09:35:24 ON 04 JAN 2011)

FILE 'REGISTRY' ENTERED AT 09:35:33 ON 04 JAN 2011
L1 STRUCTURE UPLOADED
L2 0 S L1 SSS SAM
L3 72 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 09:36:22 ON 04 JAN 2011
L4 57 S L3
L5 6 S L4 AND AD<20031020
L6 6 DUP REM L5 (0 DUPLICATES REMOVED)

=> file medline embase biosis

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	43.84	240.93
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.22	-5.22

FILE 'MEDLINE' ENTERED AT 09:42:47 ON 04 JAN 2011

FILE 'EMBASE' ENTERED AT 09:42:47 ON 04 JAN 2011

FILE 'BIOSIS' ENTERED AT 09:42:47 ON 04 JAN 2011

=> s l4
L7 0 L4

=> d his

(FILE 'HOME' ENTERED AT 09:35:24 ON 04 JAN 2011)

FILE 'REGISTRY' ENTERED AT 09:35:33 ON 04 JAN 2011
L1 STRUCTURE UPLOADED
L2 0 S L1 SSS SAM
L3 72 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 09:36:22 ON 04 JAN 2011
L4 57 S L3
L5 6 S L4 AND AD<20031020
L6 6 DUP REM L5 (0 DUPLICATES REMOVED)

```
     FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 09:42:47 ON 04 JAN 2011
L7             0 S L4

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       7.70     248.63

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -5.22

STN INTERNATIONAL LOGOFF AT 09:42:59 ON 04 JAN 2011
```